Crossmark

HCG18, LEF1AS1 and lncCEACAM21 as biomarkers of disease severity in the peripheral blood mononuclear cells of COVID-19 patients

Crossref DOI link: https://doi.org/10.1186/s12967-023-04497-6

Published Online: 2023-10-26

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Greco, Simona

Made’, Alisia

Mutoli, Martina

Zhang, Lu

Piella, Santiago Nicolas

Vausort, Mélanie

Lumley, Andrew I.

Beltrami, Antonio Paolo

Srivastava, Prashant Kumar

Milani, Valentina

Boveri, Sara

Ranucci, Marco

Renna, Laura Valentina

Firat, Hüseyin

Bruno, Antonino

Spinetti, Gaia

Emanueli, Costanza

Devaux, Yvan

Martelli, Fabio http://orcid.org/0000-0002-8624-7738
Funding

Funding for this research was provided by:

Ministero della Salute (Ricerca Corrente 2023, RCR-2022-23682288, RF-2019-12368521)

Ministero della cultura (POS T4 CAL.HUB.RIA,cod. T4-AN-09)

Fondazione Telethon (4462 GGP19035A)

AFM-Téléthon (23054)

European Commission (Next Generation EU-NRRP M6C2 PNRR-MAD-2022-12375790)

Horizon 2020 Framework Programme (COVIRNA, Grant #101016072)

Fonds National de la Recherche Luxembourg (C14/BM/8225223, C17/BM/11613033, COVID-19/2020-1/14719577/miRCOVID)

Ministère de l'Enseignement Supérieur et de la Recherche

Associazione Italiana per la Ricerca sul Cancro (AIRC-MFAG, ID 22818)

Fondazione Cariplo (ID 2019-1609)

British Heart Foundation (CH/15/1/3119, RG/20/9/35101, PG/22/11063, PG/23/11369, RE/18/4/34215)
License Information

Text and Data Mining valid from 2023-10-26

Version of Record valid from 2023-10-26
More Information

Article History

Received: 21 June 2023

Accepted: 1 September 2023

First Online: 26 October 2023

Declarations

:

: Studies were performed following the ethical principles according to the Helsinki Declaration of 1975 and as revised in 2013. The IRCCS Policlinico San Donato (PSD) experimental protocol was approved by the Institutional Ethics Committee of the San Raffaele Hospital (protocol number 75/INT/2020, 20/04/2020). The IRCCS MultiMedica (MM) experimental protocol was approved by the institutional review board ethics committee (protocol number 497.2021). All the patients enrolled in these studies were asked for their informed consent as previously approved by the ethics committee of each center.

: All patients enrolled in these studies were asked for their consent for publication.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below